Phaseline

Targets › SLC6A4

SLC6A4 (Sodium-dependent serotonin transporter): drug programs, companies and trials

85 programs from 69 companies in 187 trials: 74 Phase 2, 49 Phase 4, 33 Phase 1, 31 Phase 3; Psychiatry, Oncology, Neurology; next expected readout Nov 2026.

Serotonin transporter that cotransports serotonin with one Na(+) ion in exchange for one K(+) ion and possibly one proton in an overall electroneutral transport cycle. Transports serotonin across the plasma membrane from the extracellular compartment to the cytosol thus limiting serotonin intercellular signaling. (UniProt, P31645)

Open in Phaseline: the race on SLC6A4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of PennsylvaniaVenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Posttraumatic Stress DisorderNov 2026
University of Pennsylvaniaparoxetine
Serotonin transporter inhibitor
SLC6A4Phase 4Posttraumatic Stress DisorderNov 2026
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
All India Institute of Medical Sciences, BhubaneswarDosulepin
Tricyclic antidepressant with serotonin and norepinephrine reuptake inhibition
SLC6A4, SLC6A2Phase 4Somatic Symptom Disorder (DSM-V)Nov 2026
All India Institute of Medical Sciences, BhubaneswarVenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Somatic Symptom Disorder (DSM-V)Nov 2026
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
University of MiamiDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4THADec 2026
University of CincinnatiEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 4AnxietyDec 2026
Medical University of ViennaEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 4Major Depressive Disorder (MDD)Dec 2026
Emine KanmazSertraline
Serotonin transporter inhibitor
SLC6A4Phase 4Social Anxiety DisorderDec 2026
NYU Langone HealthEscitalopram Oxalate
Serotonin transporter inhibitor
SLC6A4Phase 4Alzheimer DiseaseDec 2026
John D. Dingell VA Medical CenterTrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 4Sleep ApneaDec 2026
Tongji Universitytrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 4Depressed Insomniac Co-morbid PatientsDec 2026
University of FloridaFluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 4Musculoskeletal InjuryMar 2027
David SteffensDesvenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Major Depressive DisorderApr 2027
David SteffensSertraline
Serotonin transporter inhibitor
SLC6A4Phase 4Major Depressive DisorderApr 2027
Wake Forest University Health SciencesDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Depression; Depression in Old AgeMay 2027
Montefiore Medical CenterDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Back Pain, LowMay 2027
Wake Forest University Health SciencesFluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 4DepressionMay 2027
Shanghai Mental Health CenterSertraline
Serotonin transporter inhibitor
SLC6A4Phase 4Depression; Obsessive-Compulsive DisorderJun 2027
Sunnybrook Health Sciences CentreDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Knee OsteoarthritisJul 2027
University of Texas at AustinSertraline
Serotonin transporter inhibitor
SLC6A4Phase 4Major Depressive DisorderJul 2027
The Chaim Sheba Medical Centerfluoxetin
Selective serotonin reuptake inhibitor
SLC6A4Phase 4Velocardiofacial SyndromeAug 2027
Aarhus University HospitalDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Functional DisorderNov 2027
Poznan University of Medical SciencesEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 4Depression - Major Depressive DisorderNov 2027
Poznan University of Medical SciencesFluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 4Depression - Major Depressive DisorderNov 2027
Poznan University of Medical SciencesSertraline
Serotonin transporter inhibitor
SLC6A4Phase 4Depression - Major Depressive DisorderNov 2027
University of California, Irvinenortriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4MénièreDec 2027
Copenhagen University Hospital, RigshospitaletEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 4Obsessive-Compulsive Disorder/High Compulsive IndividualsDec 2027
Northwestern UniversityDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Knee OsteoarthritisMar 2028
Benedict AlterDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Knee Osteoarthritis (Knee OA)Dec 2028
VA Office of Research and DevelopmentTrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 4Sleep Disordered BreathingJun 2030
Chinese University of Hong KongTrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 4Mild Cognitive Impairment–
Ann & Robert H Lurie Children's Hospital of Chicagoescitalopram
Serotonin transporter inhibitor
SLC6A4Phase 3Anxiety, SeparationDec 2026
Ann & Robert H Lurie Children's Hospital of Chicagofluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 3Anxiety, SeparationDec 2026
Ann & Robert H Lurie Children's Hospital of Chicagosertraline
Serotonin transporter inhibitor
SLC6A4Phase 3Anxiety, SeparationDec 2026
Parc de Salut MarDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 3Chronic Post-surgical PainDec 2026
Harvard Medical School (HMS and HSDM)fluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 3DepressionDec 2026
SK Life ScienceCarisbamate
GABA transporter 1 (GAT-1) inhibitor
SLC6A4Phase 3SeizuresFeb 2027
Washington University School of MedicineFluvoxamine
Serotonin transporter inhibitor
SLC6A4Phase 3DeliriumApr 2027
Intra-Cellular TherapiesLumateperone
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor
HTR2A, DRD2, SLC6A4Phase 3Major Depressive Disorder; Irritability Associated With Autism Spectrum Disorder; Bipolar Depression; Schizophrenia …Apr 2027
Tanta UniversityDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 3Biliary DiseaseJun 2027
OtsukaCentanafadine (EB-1020)
Monoamine transporter inhibitor
SLC6A4, SLC6A3, SLC6A2Phase 3Attention-Deficit Hyperactivity Disorder(ADHD); Attention Deficit Hyperactivity Disorder (ADHD)Aug 2027
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Fluvoxamine
Serotonin transporter inhibitor
SLC6A4Phase 3Post-COVIDDec 2027
Dr. Inge WinterEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 3Bipolar DepressionJun 2028
Dr. Inge WinterSertraline
Serotonin transporter inhibitor
SLC6A4Phase 3Bipolar DepressionJun 2028
Dr. Inge WinterVenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 3Bipolar DepressionJun 2028
Reinier de Graaf GroepVenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 3Breast CancerJan 2029
TakedaVortioxetine
Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist
HTR1A, SLC6A4, HTR3APhase 3Major Depressive Disorder; Glioblastoma; DepressionSep 2029
JHSPH Center for Clinical TrialsEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 3Dementia–
Children's Hospital Los AngelesFluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 3Anxiety Disorders–
Wright State UniversityImipramine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Rosacea; Photosensitivity; ImipramineDec 2026
Mayo ClinicAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Interstitial Lung Disease; Refractory Chronic CoughDec 2026
Polyclinique de l'EuropeAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Inflammatory Bowel DiseasesDec 2026
M.D. Anderson Cancer CenterDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Chemotherapy-Induced Peripheral NeuropathyDec 2026
Alliance for Clinical Trials in OncologyDuloxetine Hydrochloride
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Stage II Colorectal Cancer AJCC v8Dec 2026
First Affiliated Hospital of Chongqing Medical UniversitySertraline
Serotonin transporter inhibitor
SLC6A4Phase 2Major Depressive Disorder (MDD); DepressionDec 2026
University of PennsylvaniaDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Inflammatory Bowel DiseasesMar 2027
University of MichiganEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 2Irritable Bowel Syndrome With ConstipationMar 2027
RemedyMidomafetamine
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 2Post Traumatic Stress DisorderMar 2027
University of NebraskaEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 2Glioma of BrainJun 2027
University of Utah5-hydroxytryptophan (5-HTP)
Serotonin precursor; increases central serotonergic neurotransmission
SLC6A4Phase 2Major Depressive DisorderJul 2027
Yan Yang, MD, Ph.DDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Chemotherapy-induced Peripheral NeuropathyJul 2027
Centre hospitalier de l'Université de Montréal (CHUM)Trazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 2Insomnia ChronicJul 2027
Definium Therapeutics USMidomafetamine (DT402)
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 2Autism Spectrum DisorderAug 2027
Holland Bloorview Kids Rehabilitation HospitalSertraline
Serotonin transporter inhibitor
SLC6A4Phase 2Neurodevelopmental DisordersSep 2027
First Affiliated Hospital of Wenzhou Medical UniversityFluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 2Hepatobiliary MalignancyOct 2027
Memorial Sloan Kettering Cancer CenterFlibanserin
Serotonin 1A receptor agonist, serotonin 2A receptor antagonist, and serotonin reuptake in
HTR1A, HTR2A, SLC6A4Phase 2Breast CancerOct 2027
University of RochesterDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Painful Peripheral NeuropathyJun 2028
Nova Scotia Health Authorityfluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 2DepressionJun 2028
Wright State UniversityAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2RosaceaDec 2028
University of Texas Southwestern Medical CenterEscitalopram
Serotonin transporter inhibitor
SLC6A4Phase 2AsthmaDec 2028
National Institute of Mental Health (NIMH)Fluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 2Anxiety DisordersJan 2029
University of MichiganAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Quiescent Crohn's Disease (CD)Dec 2029
Centre Hospitalier St AnneTrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 2Depression - Major Depressive DisorderDec 2029
AlgoTherapeutixATX01 10%
Amitriptyline hydrochloride topical formulation; tricyclic antidepressant with analgesic p
SLC6A4, SLC6A3Phase 2Chemotherapy-induced Peripheral Neuropathy–
Md. Moktadirul Hoque ShuvoAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Functional Dyspepsia–
First Affiliated Hospital of Chongqing Medical UniversityDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 1DepressionDec 2026
First Affiliated Hospital of Chongqing Medical UniversityFluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 1DepressionDec 2026
Resilient PharmaceuticalsMidomafetamine
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 1Healthy Volunteers; Post-Traumatic Stress Disorder; PTSD, Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder …Feb 2027
Jonsson Comprehensive Cancer CenterFluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 1Colorectal AdenocarcinomaJul 2027
Yale UniversityFluoxetine
Serotonin transporter inhibitor
SLC6A4Phase 1Obsessive-Compulsive DisorderSep 2027
Deepak C. D'SouzaDMT
Serotonin receptor agonist; hallucinogenic indoleamine
SLC6A4Phase 1Major Depression DisorderDec 2027
Icahn School of Medicine at Mount SinaiMDMA-AT-BN
MDMA-assisted psychotherapy specific to bulimia nervosa
SLC6A4Phase 1Bulimia NervosaApr 2028
Rachel YehudaMDMA Hydrochloride
Serotonin-norepinephrine-dopamine releasing agent; promotes prosocial behavior and emotion
SLC6A4, SLC6A2, SLC6A3Phase 1Mental WellbeingSep 2029

Conditions

Depression (9) Major Depressive Disorder (6) Post Traumatic Stress Disorder (6) Depression - Major Depressive Disorder (5) Schizophrenia (5) Posttraumatic Stress Disorder (4) Bipolar Depression (4) Obstructive Sleep Apnea (4) Anxiety, Separation (3) Obsessive-Compulsive Disorder (3) Major Depressive Disorder (MDD) (2) Rosacea (2)

Modalities

small molecule (82), mixed (2)

Companies

University of Pennsylvania (4) First Affiliated Hospital of Chongqing Medical University (3) Poznan University of Medical Sciences (3) Ann & Robert H Lurie Children's Hospital of Chicago (3) Dr. Inge Winter (3) Wright State University (2) University of Michigan (2) David Steffens (2) Wake Forest University Health Sciences (2) All India Institute of Medical Sciences, Bhubaneswar (2) Aarhus University Hospital (1) Parc de Salut Mar (1) Rachel Yehuda (1) University of Miami (1) Intra-Cellular Therapies (1) The Chaim Sheba Medical Center (1) SK Life Science (1) Memorial Sloan Kettering Cancer Center (1) Reinier de Graaf Groep (1) Northwestern University (1)

Related targets

SLC6A2 (34) HTR2A (10) HTR2C (8) SLC6A3 (6) HTR1A (2) OPRM1 (2) DRD2 (1) SLC5A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) NR3C2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.